REGENXBIO Inc. Common Stock (RGNX)

FairStock Score: 28/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach REGENXBIO as a Graham-style investor: first ask whether the numbers are durable, then what the price demands. This is a clinical-stage gene-therapy company with a proprietary NAV Technology Platform and pipeline candidates including ABBV-RGX-314 and RGX-202. The science may be promising, but a durable competitive moat is unproven until approvals, reimbursement, and commercial execution exist. The filed figures show lumpy progress. In fiscal year 2023, the year ended 2023-12-31, revenue was $90.2M and net loss was $263.5M; in fiscal year 2024, the year ended 2024-12-31, revenue was $83.3M and net loss was $227.1M; in fiscal year 2025, the year ended 2025-12-31, revenue was $170.4M and net loss was $193.9M. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $108.0M and net income was $22.7M, with diluted EPS of $0.43. That one profitable quarter is encouraging, but fiscal Q1 2026, the quarter ended 2026-03-31, had revenue of $6.4M and a net loss of $90.1M, or diluted EPS of -$1.72. So profitability is not yet consistent. At the close on 2026-10-13, the price was $7.26 and market cap was $479.3M. FairStock calculations show P/E -1.92, P/B 5.50, ROE -137.63%, ROCE -21.20%, D/E 3.49, TTM FCF -$249.7M, and FCF yield -52.1%. The Altman Z-score of -2.40 and FairStock score of 28/100 point to financial fragility. The Piotroski F-score is 6/9, better but not decisive. The Lynch category is none because the company had losses in each of the last four years. Until revenue repeats and cash burn falls, this looks more like a pipeline option than a Graham-style bargain.

In plain English: REGENXBIO is a drug developer whose gene-based medicines are still being tested, mainly for eye diseases. It has lost money in recent years, but one recent quarter showed a profit after a big jump in revenue. At the latest close of $7.26, the shares look expensive compared with current profits and the cash the business uses, so the value depends heavily on future tests and approvals.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer